Araris Biotech AG is a Swiss-headquartered firm pioneering the event of its novel antibody-drug conjugate (ADC)-linker know-how to allow environment friendly and exact manufacturing of ADCs. 

Its linker platform permits the attachment of any drug payload to ‘off the shelf’ antibodies, with out the necessity for prior antibody engineering. 

The ensuing ADCs have proven very excessive exercise at low doses and an improved therapeutic index in comparison with a number of FDA-approved ADCs. Araris is a spin-off firm from the Paul Scherrer Institute (PSI) and ETH Zurich.

In October, the corporate closed a $24 million financing spherical, bringing the whole funds raised to $40 million so far.

The spherical was co-led by 4BIO Capital and Pureos Bioventures, with participation from new buyers, together with Wille AG and the Institute for Follicular Lymphoma Innovation. The spherical additionally included participation from current buyers VI Companions, Schroders Capital, btov Companions and Redalpine. Damir Illich, Ph.D. from Wille AG and Sophie Allauzen, Ph.D. from the Institute for Follicular Lymphoma Innovation may even be becoming a member of the Araris workforce as board observers.

Proceeds from the financing might be used to assist the additional growth and development of Araris’ antibody-drug conjugate (ADC) candidates, created utilizing the Firm’s proprietary linker know-how, as Araris strikes nearer in direction of scientific growth.

At Bio-Europe, we chatted with Philipp Spycher, chief government officer of Araris Biotech.

Source link